Boulevard Bio has officially launched from stealth, securing $65 million in financing from its founding investor, Deerfield Management. The precision immunology company is focused on developing multi-specific medicines for B cell-driven autoimmune diseases. Early Phase 1 data for its lead candidate, BLVD101, suggests a promising quarterly dosing schedule for patients with IgA nephropathy.
A New Approach to Autoimmune Disease
The company aims to shift the treatment paradigm for the millions of patients living with chronic B cell-driven autoimmune conditions. CEO Mahesh Karande stated the goal is to offer durable disease control and potentially a cure, freeing patients from a lifetime of burdensome treatments. This mission is guided by a world-class founding team with deep expertise in B cell biology and immunology.
Promising Lead Candidate
The company's lead asset, BLVD101, is a bispecific antibody that targets both BAFF and APRIL, key drivers in IgA nephropathy (IgAN). Interim Phase 1 results from a study in healthy volunteers showed the drug was well-tolerated and supported a 12-week dosing interval. This quarterly schedule is designed to align with routine patient care and reduce treatment burden for chronic illness.
BLVD101 was invented and developed within Deerfield Discovery and Development (3DC), the investment firm's internal research engine. Data from the single-ascending dose study demonstrated a favorable safety profile and strong IgA suppression, supporting its best-in-class potential. These results suggest that blocking both targets could effectively slow disease progression and reduce disease burden across multiple autoimmune conditions.
Expanding the Pipeline
Beyond its lead program, Boulevard is advancing a diverse pipeline to address severe autoimmune diseases. Its second candidate, BLVD201, is a trispecific T cell engager designed to deliver a durable immune reset by targeting multiple B cell markers. The company is also progressing BLVD301, a development candidate directed at a novel target combination with strong genetic validation.
The design of BLVD201 aims to clear antibody-producing cells and the cells that replenish them, a strategy intended to overcome limitations of single-target therapies. This program, currently in IND-enabling studies, was acquired from METiS TechBio under an exclusive global license. Meanwhile, BLVD301 was nominated as a development candidate in June 2026, further broadening the company's therapeutic scope.
Strategic Leadership and Backing
Boulevard Bio is led by CEO Mahesh Karande and Chief Medical Officer Dr. Neil Solomons, with significant oversight from its investor. The company's board is chaired by a managing director at Deerfield Management, which provided the entire $65 million in financing. This substantial backing and experienced leadership position the company to advance its innovative therapeutic programs through clinical development.
The company was co-founded by renowned rheumatology expert Prof. Georg Schett, alongside scientific co-founder Dr. Frank Nestle, who also serves as CEO of Deerfield's 3DC. This deep scientific foundation is central to Boulevard's strategy of pairing specific targets and modalities to the right diseases. The company is headquartered in New York City at Cure, an affiliate of Deerfield.
With a substantial $65 million in funding and a clear strategic vision, Boulevard Bio enters the immunology landscape poised to make a significant impact. The company's multi-specific antibody platform, led by the promising BLVD101, reflects a commitment to developing more effective and convenient treatments. Its focus on addressing the underlying causes of B cell-driven diseases holds the potential to redefine therapeutic standards for patients worldwide.